TMP-SMX Effect(s) on Renal Function and Population Factors that may increase the risk of AKI

Class of 2021 Abstract, Report and PosterSpecific Aims: To explore what patient specific factors may predispose an individual to experiencing a true Acute Kidney Injury (AKI) with Sulfamethoxazole Trimethoprim (TMP/SMX) in the first 10 days of treatment. The findings then can be used by providers to better differentiate a true AKI from pseudo renal failure when they notice an increase in serum creatinine (sCr) due to TMP/SMX. Subjects: Patients will be included in the study if they are: adults (18 years of age or older), who at the time of TMP/SMX initiation had stable renal function and received a TMP/SMX dose of ≥ 160mg/800mg for at least 72 hours. Methods: Using the facility’s electronic health record system (Cerner) we generated a report of patients who received a minimum daily dose of TMP ≥320 mg and were discharged between March 01 2020 and August 31 2020. Main Results: Of the 102 patients screened from Banner University Medical Center Tucson that we screened 23 patients met our inclusion criteria. AKI was found in 8 of the 23 subjects and was more common with increased comorbidities, nephrotoxic drugs, and contrast agents, supporting current literature. Conclusions: In our 8 subjects with AKI, we found that occurrence of AKI occurred in the setting of multiple comorbidities and/or with nephrotoxic agents.This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu